| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 130 | 2024 | 3029 | 9.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 125 | 2024 | 5671 | 6.310 |
Why?
|
| Bone Marrow Transplantation | 90 | 2023 | 2693 | 3.510 |
Why?
|
| Interleukin-2 | 55 | 2023 | 1889 | 3.370 |
Why?
|
| Transplantation, Homologous | 101 | 2024 | 4806 | 3.030 |
Why?
|
| Killer Cells, Natural | 75 | 2024 | 2200 | 3.020 |
Why?
|
| T-Lymphocytes, Regulatory | 31 | 2024 | 3080 | 2.860 |
Why?
|
| Lymphocyte Transfusion | 24 | 2021 | 232 | 2.860 |
Why?
|
| T-Lymphocytes | 89 | 2024 | 10194 | 2.200 |
Why?
|
| Hematologic Neoplasms | 39 | 2024 | 1896 | 2.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 25 | 2013 | 686 | 2.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 33 | 2023 | 4369 | 1.890 |
Why?
|
| Lymphocyte Depletion | 34 | 2016 | 602 | 1.870 |
Why?
|
| Transplantation Conditioning | 38 | 2024 | 1590 | 1.840 |
Why?
|
| Lymphocyte Activation | 68 | 2022 | 5486 | 1.710 |
Why?
|
| Cord Blood Stem Cell Transplantation | 11 | 2019 | 305 | 1.700 |
Why?
|
| Antigens, Surface | 44 | 2017 | 1606 | 1.690 |
Why?
|
| CD8-Positive T-Lymphocytes | 27 | 2024 | 4580 | 1.650 |
Why?
|
| Laparoscopy | 7 | 2023 | 2035 | 1.590 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 33 | 2022 | 899 | 1.580 |
Why?
|
| Immunotherapy, Adoptive | 15 | 2024 | 1469 | 1.520 |
Why?
|
| B-Lymphocytes | 46 | 2024 | 4758 | 1.470 |
Why?
|
| Leukemia, Myeloid, Acute | 30 | 2024 | 3613 | 1.420 |
Why?
|
| Interleukin-12 | 19 | 2002 | 584 | 1.370 |
Why?
|
| Ileostomy | 4 | 2016 | 121 | 1.280 |
Why?
|
| Graft vs Tumor Effect | 9 | 2016 | 68 | 1.200 |
Why?
|
| Antigens, CD | 43 | 2024 | 4003 | 1.180 |
Why?
|
| T-Lymphocyte Subsets | 16 | 2019 | 1802 | 1.180 |
Why?
|
| Antigens, Neoplasm | 43 | 2024 | 1993 | 1.150 |
Why?
|
| Transplantation Chimera | 12 | 2015 | 594 | 1.140 |
Why?
|
| B-Cell Activating Factor | 8 | 2014 | 115 | 1.140 |
Why?
|
| Cytotoxicity, Immunologic | 40 | 2016 | 1351 | 1.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 7 | 2014 | 694 | 1.090 |
Why?
|
| Flow Cytometry | 25 | 2017 | 5869 | 1.040 |
Why?
|
| Receptors, Interleukin-2 | 22 | 2006 | 562 | 1.030 |
Why?
|
| Leukemia, Lymphoid | 34 | 2005 | 310 | 1.010 |
Why?
|
| Graft vs Leukemia Effect | 12 | 2024 | 121 | 0.990 |
Why?
|
| Antibodies, Monoclonal | 99 | 2023 | 9177 | 0.980 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 18 | 2021 | 1640 | 0.980 |
Why?
|
| Chronic Disease | 43 | 2022 | 9318 | 0.970 |
Why?
|
| Isoantibodies | 10 | 2019 | 674 | 0.930 |
Why?
|
| Myelodysplastic Syndromes | 17 | 2024 | 1394 | 0.910 |
Why?
|
| Hematopoietic Stem Cells | 22 | 2023 | 3396 | 0.900 |
Why?
|
| Leukemia | 27 | 2024 | 1522 | 0.880 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.840 |
Why?
|
| Humans | 482 | 2024 | 761504 | 0.810 |
Why?
|
| BK Virus | 2 | 2020 | 123 | 0.810 |
Why?
|
| Bronchiolitis Obliterans | 9 | 2022 | 213 | 0.800 |
Why?
|
| Sigmoid Diseases | 2 | 2013 | 59 | 0.800 |
Why?
|
| B-Lymphocyte Subsets | 3 | 2015 | 239 | 0.790 |
Why?
|
| Antilymphocyte Serum | 6 | 2019 | 487 | 0.780 |
Why?
|
| Myeloablative Agonists | 8 | 2018 | 209 | 0.770 |
Why?
|
| Forkhead Transcription Factors | 7 | 2013 | 1616 | 0.770 |
Why?
|
| Anesthesia, Epidural | 1 | 2023 | 233 | 0.750 |
Why?
|
| HLA Antigens | 17 | 2020 | 1328 | 0.750 |
Why?
|
| Diverticulitis, Colonic | 2 | 2013 | 138 | 0.730 |
Why?
|
| Recurrence | 50 | 2024 | 8465 | 0.730 |
Why?
|
| Multiple Myeloma | 21 | 2024 | 5146 | 0.720 |
Why?
|
| Intestinal Diseases | 3 | 2016 | 504 | 0.700 |
Why?
|
| Minor Histocompatibility Antigens | 5 | 2011 | 293 | 0.690 |
Why?
|
| Adult | 195 | 2024 | 221177 | 0.680 |
Why?
|
| Transplantation, Autologous | 38 | 2021 | 2115 | 0.670 |
Why?
|
| Colorectal Neoplasms | 5 | 2023 | 6935 | 0.670 |
Why?
|
| Lymphoma, Non-Hodgkin | 17 | 2017 | 1374 | 0.660 |
Why?
|
| Hodgkin Disease | 5 | 2021 | 1378 | 0.650 |
Why?
|
| Fusion Proteins, bcr-abl | 8 | 2007 | 431 | 0.650 |
Why?
|
| Middle Aged | 176 | 2024 | 220895 | 0.650 |
Why?
|
| Homeostasis | 5 | 2015 | 3323 | 0.640 |
Why?
|
| Clone Cells | 39 | 2017 | 1659 | 0.630 |
Why?
|
| H-Y Antigen | 3 | 2015 | 42 | 0.600 |
Why?
|
| Gene Expression Regulation, Leukemic | 7 | 2024 | 651 | 0.600 |
Why?
|
| Male | 211 | 2024 | 360804 | 0.590 |
Why?
|
| Antibodies, Neoplasm | 9 | 2002 | 281 | 0.590 |
Why?
|
| Receptors, Interleukin | 8 | 2021 | 243 | 0.590 |
Why?
|
| Cancer Vaccines | 9 | 2024 | 1051 | 0.580 |
Why?
|
| Antibodies | 10 | 2017 | 2418 | 0.570 |
Why?
|
| Female | 213 | 2024 | 392644 | 0.560 |
Why?
|
| Stem Cell Transplantation | 8 | 2021 | 1600 | 0.560 |
Why?
|
| Surgical Wound Infection | 3 | 2016 | 1527 | 0.550 |
Why?
|
| Lymphoma | 19 | 2018 | 1901 | 0.550 |
Why?
|
| Receptors, Antigen, T-Cell | 21 | 2019 | 2547 | 0.540 |
Why?
|
| Robotics | 1 | 2023 | 819 | 0.530 |
Why?
|
| Cells, Cultured | 26 | 2021 | 18965 | 0.520 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2017 | 1551 | 0.520 |
Why?
|
| Mass Spectrometry | 3 | 2017 | 2192 | 0.510 |
Why?
|
| Immunologic Memory | 9 | 2024 | 1359 | 0.510 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2019 | 974 | 0.510 |
Why?
|
| Tissue Donors | 16 | 2024 | 2331 | 0.500 |
Why?
|
| Drug Resistance | 4 | 2019 | 1596 | 0.490 |
Why?
|
| Immunophenotyping | 16 | 2018 | 1870 | 0.490 |
Why?
|
| Antigens, CD19 | 4 | 2020 | 424 | 0.480 |
Why?
|
| Herpesvirus 4, Human | 11 | 2023 | 1078 | 0.480 |
Why?
|
| Aged | 107 | 2024 | 169289 | 0.480 |
Why?
|
| Histocompatibility | 3 | 2012 | 317 | 0.470 |
Why?
|
| Plasma Cells | 4 | 2016 | 599 | 0.470 |
Why?
|
| Germinal Center | 4 | 2022 | 380 | 0.470 |
Why?
|
| Immunotoxins | 9 | 1997 | 175 | 0.470 |
Why?
|
| Burkitt Lymphoma | 10 | 2005 | 335 | 0.460 |
Why?
|
| Steroids | 8 | 2022 | 929 | 0.460 |
Why?
|
| DNA-Binding Proteins | 16 | 2021 | 9606 | 0.460 |
Why?
|
| Postoperative Complications | 13 | 2023 | 15631 | 0.450 |
Why?
|
| Interferon-gamma | 17 | 2020 | 3162 | 0.450 |
Why?
|
| Virus Diseases | 3 | 2021 | 718 | 0.450 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2024 | 891 | 0.450 |
Why?
|
| Neoplasms | 20 | 2024 | 22170 | 0.450 |
Why?
|
| T-Lymphocytes, Cytotoxic | 11 | 2024 | 1784 | 0.450 |
Why?
|
| Trans-Activators | 9 | 2001 | 2856 | 0.440 |
Why?
|
| Leukocytes, Mononuclear | 12 | 2016 | 1844 | 0.440 |
Why?
|
| Ricin | 7 | 1997 | 70 | 0.430 |
Why?
|
| Tacrolimus | 8 | 2023 | 733 | 0.420 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2014 | 828 | 0.410 |
Why?
|
| Leukemia, B-Cell | 2 | 2011 | 84 | 0.410 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 5 | 2016 | 263 | 0.410 |
Why?
|
| Bone Marrow Cells | 21 | 2013 | 2416 | 0.410 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 819 | 0.410 |
Why?
|
| Fetal Blood | 7 | 2019 | 1347 | 0.410 |
Why?
|
| Interleukins | 7 | 2021 | 782 | 0.410 |
Why?
|
| Immunosuppressive Agents | 10 | 2020 | 4174 | 0.400 |
Why?
|
| Hematopoiesis | 13 | 2023 | 2049 | 0.400 |
Why?
|
| Antigens, CD34 | 7 | 2024 | 658 | 0.400 |
Why?
|
| Tumor Escape | 3 | 2023 | 370 | 0.400 |
Why?
|
| Janus Kinase 1 | 1 | 2012 | 107 | 0.400 |
Why?
|
| Surgical Equipment | 1 | 2012 | 57 | 0.400 |
Why?
|
| Erythropoiesis | 6 | 2021 | 683 | 0.400 |
Why?
|
| Rectum | 2 | 2023 | 892 | 0.390 |
Why?
|
| Signal Transduction | 27 | 2021 | 23445 | 0.370 |
Why?
|
| Young Adult | 46 | 2024 | 59243 | 0.360 |
Why?
|
| Graft Survival | 14 | 2017 | 3819 | 0.360 |
Why?
|
| Immunologic Factors | 4 | 2014 | 1589 | 0.360 |
Why?
|
| Bone Marrow | 28 | 2005 | 2911 | 0.350 |
Why?
|
| Acute Disease | 21 | 2017 | 7237 | 0.350 |
Why?
|
| Colorectal Surgery | 1 | 2012 | 122 | 0.350 |
Why?
|
| Lymphocytes | 15 | 2014 | 2612 | 0.350 |
Why?
|
| Vidarabine | 7 | 2019 | 336 | 0.340 |
Why?
|
| Cell Culture Techniques | 3 | 2017 | 1667 | 0.340 |
Why?
|
| Viral Matrix Proteins | 4 | 2020 | 196 | 0.340 |
Why?
|
| Complement System Proteins | 14 | 1994 | 736 | 0.340 |
Why?
|
| Cyclophosphamide | 15 | 2023 | 2218 | 0.340 |
Why?
|
| Leukemia, Myeloid | 12 | 2021 | 694 | 0.340 |
Why?
|
| Length of Stay | 5 | 2023 | 6425 | 0.340 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 4 | 2016 | 306 | 0.340 |
Why?
|
| Immunotherapy | 13 | 2023 | 4652 | 0.340 |
Why?
|
| Janus Kinase 2 | 2 | 2012 | 560 | 0.340 |
Why?
|
| Pyrimidines | 6 | 2017 | 3028 | 0.330 |
Why?
|
| Cell Communication | 5 | 2011 | 1657 | 0.330 |
Why?
|
| Colonic Pouches | 1 | 2010 | 122 | 0.320 |
Why?
|
| Anemia, Sickle Cell | 4 | 2020 | 1063 | 0.320 |
Why?
|
| Chromosomes, Human, Y | 1 | 2010 | 161 | 0.320 |
Why?
|
| Myeloproliferative Disorders | 2 | 2016 | 613 | 0.320 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2010 | 218 | 0.320 |
Why?
|
| Anastomotic Leak | 2 | 2023 | 163 | 0.320 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2010 | 190 | 0.310 |
Why?
|
| Single-Cell Analysis | 3 | 2024 | 2449 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2020 | 4511 | 0.310 |
Why?
|
| Immunity | 2 | 2021 | 996 | 0.300 |
Why?
|
| Intestinal Perforation | 3 | 2016 | 249 | 0.300 |
Why?
|
| Lymphoma, Follicular | 5 | 2024 | 457 | 0.290 |
Why?
|
| Whole-Body Irradiation | 12 | 2019 | 433 | 0.290 |
Why?
|
| Treatment Outcome | 54 | 2024 | 64680 | 0.290 |
Why?
|
| Epitopes | 10 | 2023 | 2503 | 0.290 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 5 | 2020 | 95 | 0.290 |
Why?
|
| Natural Killer T-Cells | 2 | 2024 | 322 | 0.290 |
Why?
|
| Animals | 86 | 2024 | 168459 | 0.290 |
Why?
|
| Cytokines | 17 | 2024 | 7396 | 0.280 |
Why?
|
| Receptors, Immunologic | 13 | 1994 | 1410 | 0.280 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2006 | 11 | 0.280 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2016 | 226 | 0.280 |
Why?
|
| STAT5 Transcription Factor | 5 | 2017 | 265 | 0.280 |
Why?
|
| Dermatology | 1 | 2017 | 918 | 0.280 |
Why?
|
| Protein-Tyrosine Kinases | 10 | 2015 | 2425 | 0.270 |
Why?
|
| Disease-Free Survival | 23 | 2019 | 6814 | 0.270 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 1405 | 0.270 |
Why?
|
| Busulfan | 6 | 2018 | 258 | 0.270 |
Why?
|
| Integrins | 3 | 2009 | 834 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 7407 | 0.270 |
Why?
|
| Survival Analysis | 24 | 2018 | 10090 | 0.270 |
Why?
|
| Telomerase | 1 | 2011 | 745 | 0.270 |
Why?
|
| Lymphocyte Count | 6 | 2019 | 778 | 0.260 |
Why?
|
| Appendectomy | 1 | 2009 | 433 | 0.260 |
Why?
|
| Immunity, Innate | 5 | 2011 | 3065 | 0.260 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2006 | 108 | 0.260 |
Why?
|
| Thymus Gland | 5 | 2010 | 1243 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 15 | 2008 | 6132 | 0.260 |
Why?
|
| Neoplasm Proteins | 11 | 2021 | 3617 | 0.260 |
Why?
|
| Mice | 58 | 2024 | 81525 | 0.250 |
Why?
|
| STAT Transcription Factors | 1 | 2006 | 188 | 0.250 |
Why?
|
| Piperazines | 4 | 2016 | 2523 | 0.250 |
Why?
|
| Gene Expression Profiling | 12 | 2024 | 9420 | 0.250 |
Why?
|
| Mutation | 18 | 2024 | 30052 | 0.250 |
Why?
|
| Suction | 2 | 2016 | 266 | 0.250 |
Why?
|
| Erythroblasts | 1 | 2005 | 142 | 0.240 |
Why?
|
| DNA, Neoplasm | 11 | 2016 | 1745 | 0.240 |
Why?
|
| Down-Regulation | 6 | 2020 | 2919 | 0.240 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 113 | 0.240 |
Why?
|
| Immune Tolerance | 5 | 2019 | 2303 | 0.240 |
Why?
|
| Erythroid Cells | 2 | 2021 | 238 | 0.230 |
Why?
|
| Antineoplastic Agents | 12 | 2024 | 13639 | 0.230 |
Why?
|
| Reoperation | 4 | 2022 | 4303 | 0.230 |
Why?
|
| Isoantigens | 3 | 2006 | 551 | 0.230 |
Why?
|
| Dioxygenases | 3 | 2021 | 345 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2020 | 11742 | 0.230 |
Why?
|
| Proteins | 3 | 2022 | 6032 | 0.230 |
Why?
|
| Colectomy | 1 | 2009 | 688 | 0.230 |
Why?
|
| Paraproteinemias | 1 | 2006 | 248 | 0.230 |
Why?
|
| Bone Marrow Purging | 5 | 1998 | 108 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2014 | 8547 | 0.230 |
Why?
|
| Peptide Fragments | 4 | 2016 | 5112 | 0.230 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2016 | 278 | 0.230 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2004 | 37 | 0.220 |
Why?
|
| Leukemia, Experimental | 4 | 2020 | 225 | 0.220 |
Why?
|
| Models, Immunological | 4 | 2016 | 513 | 0.220 |
Why?
|
| Interleukin-4 | 7 | 2017 | 1149 | 0.220 |
Why?
|
| Follow-Up Studies | 28 | 2020 | 39106 | 0.220 |
Why?
|
| Antibody Formation | 6 | 2017 | 1395 | 0.220 |
Why?
|
| Receptors, Interleukin-12 | 6 | 2002 | 26 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 16 | 2020 | 6216 | 0.220 |
Why?
|
| Carcinoma, Small Cell | 2 | 1997 | 420 | 0.210 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 2 | 2022 | 263 | 0.210 |
Why?
|
| Antibody Specificity | 13 | 2011 | 1060 | 0.210 |
Why?
|
| DNA Fingerprinting | 2 | 2022 | 114 | 0.210 |
Why?
|
| Blood Donors | 6 | 2013 | 345 | 0.210 |
Why?
|
| Combined Modality Therapy | 17 | 2019 | 8529 | 0.210 |
Why?
|
| Skin Diseases | 4 | 2020 | 1094 | 0.200 |
Why?
|
| Fetal Proteins | 1 | 2022 | 98 | 0.200 |
Why?
|
| Adolescent | 49 | 2024 | 88319 | 0.200 |
Why?
|
| Clinical Trials as Topic | 11 | 2021 | 8002 | 0.200 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 585 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 9 | 2012 | 3778 | 0.200 |
Why?
|
| Cell Division | 16 | 2006 | 4465 | 0.200 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 2001 | 111 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 3 | 1999 | 1036 | 0.200 |
Why?
|
| Dendritic Cells | 5 | 2024 | 2747 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 17 | 2010 | 6075 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 9280 | 0.200 |
Why?
|
| Phenotype | 30 | 2024 | 16591 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 2 | 2023 | 831 | 0.190 |
Why?
|
| Cell Separation | 16 | 2016 | 1720 | 0.190 |
Why?
|
| Leukopoiesis | 1 | 2001 | 54 | 0.190 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1999 | 489 | 0.190 |
Why?
|
| Boronic Acids | 4 | 2014 | 915 | 0.190 |
Why?
|
| Virus Activation | 3 | 2019 | 322 | 0.190 |
Why?
|
| Cell Line, Tumor | 14 | 2024 | 16981 | 0.190 |
Why?
|
| Retrospective Studies | 36 | 2024 | 80636 | 0.190 |
Why?
|
| Gene Rearrangement | 6 | 2005 | 1125 | 0.190 |
Why?
|
| Molecular Sequence Data | 16 | 2006 | 17635 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 191 | 0.180 |
Why?
|
| Mitochondria | 1 | 2014 | 3624 | 0.180 |
Why?
|
| Prognosis | 32 | 2019 | 29625 | 0.180 |
Why?
|
| Cell Differentiation | 16 | 2020 | 11528 | 0.180 |
Why?
|
| Opportunistic Infections | 1 | 2023 | 376 | 0.180 |
Why?
|
| K562 Cells | 6 | 2024 | 642 | 0.180 |
Why?
|
| Treatment Failure | 2 | 2024 | 2645 | 0.180 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 976 | 0.180 |
Why?
|
| Neoplasm, Residual | 4 | 2022 | 1008 | 0.180 |
Why?
|
| Genes, abl | 2 | 2007 | 69 | 0.180 |
Why?
|
| Gene Library | 6 | 2014 | 1059 | 0.180 |
Why?
|
| Transplantation Immunology | 5 | 2016 | 532 | 0.180 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 4 | 2007 | 164 | 0.180 |
Why?
|
| Apoptosis | 9 | 2017 | 9486 | 0.180 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2024 | 1860 | 0.180 |
Why?
|
| Immunoconjugates | 3 | 2017 | 954 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 3602 | 0.180 |
Why?
|
| Catheters | 1 | 2023 | 427 | 0.180 |
Why?
|
| Coculture Techniques | 2 | 2016 | 1341 | 0.170 |
Why?
|
| Gene Expression | 10 | 2016 | 7581 | 0.170 |
Why?
|
| Remission Induction | 9 | 2012 | 2396 | 0.170 |
Why?
|
| gamma-Globins | 1 | 2020 | 106 | 0.170 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 67 | 0.170 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2000 | 71 | 0.170 |
Why?
|
| Pyrazines | 4 | 2014 | 1201 | 0.170 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2011 | 384 | 0.170 |
Why?
|
| Recovery of Function | 3 | 2019 | 2979 | 0.170 |
Why?
|
| Th17 Cells | 2 | 2016 | 794 | 0.170 |
Why?
|
| Complementarity Determining Regions | 1 | 2000 | 149 | 0.170 |
Why?
|
| Antigens, Differentiation | 7 | 1995 | 910 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 865 | 0.160 |
Why?
|
| Cell Lineage | 5 | 2016 | 2555 | 0.160 |
Why?
|
| Up-Regulation | 9 | 2011 | 4124 | 0.160 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 88 | 0.160 |
Why?
|
| Time Factors | 26 | 2021 | 39967 | 0.160 |
Why?
|
| Survival Rate | 17 | 2021 | 12725 | 0.160 |
Why?
|
| Photopheresis | 1 | 2019 | 35 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2010 | 220 | 0.160 |
Why?
|
| Histocompatibility Testing | 6 | 2015 | 712 | 0.160 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 5 | 2002 | 303 | 0.160 |
Why?
|
| Blotting, Western | 6 | 2011 | 5035 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 5 | 2002 | 800 | 0.150 |
Why?
|
| RNA Interference | 2 | 2020 | 2831 | 0.150 |
Why?
|
| Biopsy | 4 | 2023 | 6766 | 0.150 |
Why?
|
| Certification | 1 | 2022 | 418 | 0.150 |
Why?
|
| Colitis, Ulcerative | 1 | 2010 | 1922 | 0.150 |
Why?
|
| Cell Transplantation | 2 | 2012 | 472 | 0.150 |
Why?
|
| Life Tables | 8 | 2003 | 364 | 0.150 |
Why?
|
| Phosphorylation | 15 | 2021 | 8320 | 0.150 |
Why?
|
| Recombinant Proteins | 12 | 2009 | 6534 | 0.150 |
Why?
|
| Immunoglobulin G | 9 | 2011 | 4544 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2017 | 1405 | 0.150 |
Why?
|
| Gene Deletion | 3 | 2019 | 2665 | 0.150 |
Why?
|
| Prospective Studies | 15 | 2023 | 54425 | 0.150 |
Why?
|
| Fetal Hemoglobin | 1 | 2020 | 345 | 0.150 |
Why?
|
| Commerce | 1 | 2023 | 606 | 0.150 |
Why?
|
| Cell Line | 36 | 2005 | 15601 | 0.150 |
Why?
|
| Interleukin-7 | 2 | 2015 | 143 | 0.150 |
Why?
|
| Monocytes | 9 | 2002 | 2570 | 0.150 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 2850 | 0.150 |
Why?
|
| Phosphoserine | 1 | 1997 | 203 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 435 | 0.140 |
Why?
|
| Hematologic Diseases | 3 | 2018 | 496 | 0.140 |
Why?
|
| Amniotic Fluid | 2 | 2011 | 378 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 612 | 0.140 |
Why?
|
| Cell Proliferation | 6 | 2019 | 10445 | 0.140 |
Why?
|
| Cytoplasmic Granules | 4 | 1989 | 574 | 0.140 |
Why?
|
| Feasibility Studies | 6 | 2023 | 5247 | 0.140 |
Why?
|
| Polyomavirus Infections | 1 | 2019 | 194 | 0.140 |
Why?
|
| Case-Control Studies | 9 | 2014 | 22176 | 0.140 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 382 | 0.140 |
Why?
|
| DNA, Complementary | 6 | 2014 | 1991 | 0.140 |
Why?
|
| Immunization, Passive | 4 | 1984 | 616 | 0.140 |
Why?
|
| Prednisone | 8 | 2014 | 1563 | 0.140 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2009 | 227 | 0.140 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 123 | 0.140 |
Why?
|
| Crohn Disease | 1 | 2009 | 2279 | 0.140 |
Why?
|
| Ileus | 1 | 2016 | 66 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2002 | 962 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 2019 | 438 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 9031 | 0.130 |
Why?
|
| Lymphocyte Cooperation | 1 | 2016 | 112 | 0.130 |
Why?
|
| Child | 33 | 2023 | 80153 | 0.130 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 238 | 0.130 |
Why?
|
| Biotechnology | 1 | 2018 | 282 | 0.130 |
Why?
|
| HLA-A2 Antigen | 2 | 2022 | 211 | 0.130 |
Why?
|
| Phospholipase C gamma | 1 | 2016 | 131 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 3 | 2016 | 871 | 0.130 |
Why?
|
| Vaccination | 3 | 2024 | 3384 | 0.130 |
Why?
|
| Tyrosine | 6 | 1999 | 1440 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2007 | 1606 | 0.130 |
Why?
|
| Leukocyte Count | 6 | 2014 | 1596 | 0.130 |
Why?
|
| Leukopenia | 2 | 2017 | 213 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 14 | 2024 | 22169 | 0.130 |
Why?
|
| Cytogenetic Analysis | 3 | 2007 | 270 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 1612 | 0.130 |
Why?
|
| Lymphocyte Subsets | 6 | 2013 | 310 | 0.120 |
Why?
|
| Janus Kinase 3 | 4 | 2012 | 76 | 0.120 |
Why?
|
| Melanoma | 4 | 2017 | 5709 | 0.120 |
Why?
|
| Lymphopoiesis | 1 | 2016 | 133 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 1052 | 0.120 |
Why?
|
| Cell Transformation, Viral | 4 | 2011 | 526 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 878 | 0.120 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hematopoietic System | 2 | 1995 | 110 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 4 | 2020 | 964 | 0.120 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2015 | 43 | 0.120 |
Why?
|
| Ligands | 5 | 2024 | 3272 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2017 | 1092 | 0.120 |
Why?
|
| Gammaretrovirus | 1 | 2014 | 24 | 0.120 |
Why?
|
| Stem Cell Factor | 1 | 2015 | 195 | 0.120 |
Why?
|
| Base Sequence | 14 | 2006 | 12441 | 0.120 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 1 | 2014 | 24 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2005 | 4575 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 11 | 2015 | 2469 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 5 | 2010 | 1347 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 899 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 350 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 72 | 0.120 |
Why?
|
| RNA, Messenger | 14 | 2007 | 12795 | 0.120 |
Why?
|
| Quinazolinones | 1 | 2016 | 221 | 0.120 |
Why?
|
| Herpesviridae Infections | 4 | 1989 | 270 | 0.120 |
Why?
|
| Hemolysis | 2 | 2007 | 415 | 0.120 |
Why?
|
| Epithelial Cells | 2 | 2023 | 3673 | 0.120 |
Why?
|
| Rosette Formation | 5 | 1987 | 152 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 281 | 0.120 |
Why?
|
| Hidradenitis Suppurativa | 1 | 1998 | 178 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2017 | 290 | 0.110 |
Why?
|
| Epitope Mapping | 2 | 2023 | 298 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2017 | 481 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2024 | 1978 | 0.110 |
Why?
|
| Neutrophils | 3 | 2016 | 3767 | 0.110 |
Why?
|
| Gene Expression Regulation | 11 | 2006 | 11903 | 0.110 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 943 | 0.110 |
Why?
|
| 16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Enzyme Activation | 4 | 2011 | 3597 | 0.110 |
Why?
|
| Anemia | 2 | 2021 | 1509 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 561 | 0.110 |
Why?
|
| Exoribonucleases | 2 | 2005 | 93 | 0.110 |
Why?
|
| STAT4 Transcription Factor | 4 | 2001 | 93 | 0.110 |
Why?
|
| Genomics | 2 | 2006 | 5821 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 20570 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 3639 | 0.110 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 1469 | 0.110 |
Why?
|
| B-Cell Maturation Antigen | 2 | 2024 | 149 | 0.110 |
Why?
|
| Phytohemagglutinins | 6 | 1996 | 167 | 0.110 |
Why?
|
| Leukocytes | 5 | 2014 | 2026 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2013 | 84 | 0.110 |
Why?
|
| Child, Preschool | 19 | 2023 | 42230 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 733 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 1995 | 535 | 0.110 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2013 | 223 | 0.100 |
Why?
|
| Purines | 1 | 2016 | 607 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2017 | 1085 | 0.100 |
Why?
|
| Research Design | 3 | 2017 | 6180 | 0.100 |
Why?
|
| Cytogenetics | 3 | 2007 | 198 | 0.100 |
Why?
|
| Tyrphostins | 1 | 2012 | 63 | 0.100 |
Why?
|
| Karyotyping | 6 | 2005 | 1171 | 0.100 |
Why?
|
| Adhesiveness | 1 | 2012 | 52 | 0.100 |
Why?
|
| TYK2 Kinase | 1 | 2012 | 38 | 0.100 |
Why?
|
| Viremia | 2 | 2019 | 707 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2011 | 531 | 0.100 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 6 | 1995 | 317 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2019 | 6567 | 0.100 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1994 | 283 | 0.100 |
Why?
|
| Disease Models, Animal | 10 | 2024 | 18252 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2020 | 2986 | 0.100 |
Why?
|
| Sirolimus | 1 | 2019 | 1533 | 0.100 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2012 | 74 | 0.100 |
Why?
|
| Mice, Knockout | 7 | 2024 | 14414 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2017 | 774 | 0.100 |
Why?
|
| Amino Acid Sequence | 6 | 2017 | 13446 | 0.100 |
Why?
|
| STAT1 Transcription Factor | 5 | 2001 | 341 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 3 | 1999 | 1600 | 0.100 |
Why?
|
| Membrane Glycoproteins | 5 | 2005 | 3702 | 0.100 |
Why?
|
| Azacitidine | 2 | 2024 | 336 | 0.100 |
Why?
|
| Incidence | 12 | 2023 | 21353 | 0.100 |
Why?
|
| Calcium Signaling | 1 | 2016 | 733 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 14666 | 0.100 |
Why?
|
| Oncogenes | 4 | 2024 | 1222 | 0.100 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 128 | 0.100 |
Why?
|
| Plastics | 1 | 2012 | 117 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2019 | 15936 | 0.100 |
Why?
|
| Exocytosis | 3 | 1988 | 320 | 0.100 |
Why?
|
| Peptides | 1 | 2023 | 4358 | 0.100 |
Why?
|
| Pyridones | 1 | 2017 | 809 | 0.090 |
Why?
|
| Fusarium | 1 | 1991 | 51 | 0.090 |
Why?
|
| Solubility | 3 | 2012 | 1091 | 0.090 |
Why?
|
| Receptors, IgG | 2 | 1993 | 559 | 0.090 |
Why?
|
| Methotrexate | 5 | 2018 | 1719 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 1943 | 0.090 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1990 | 52 | 0.090 |
Why?
|
| Organ Specificity | 3 | 2022 | 1967 | 0.090 |
Why?
|
| Anemia, Hemolytic | 1 | 1992 | 162 | 0.090 |
Why?
|
| Colon, Sigmoid | 1 | 2011 | 124 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6484 | 0.090 |
Why?
|
| Biological Therapy | 1 | 2012 | 141 | 0.090 |
Why?
|
| Lectins, C-Type | 3 | 1999 | 585 | 0.090 |
Why?
|
| Cryopreservation | 4 | 2021 | 728 | 0.090 |
Why?
|
| Stem Cells | 2 | 2019 | 3522 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 1991 | 547 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2016 | 629 | 0.090 |
Why?
|
| Drainage | 1 | 2016 | 1157 | 0.090 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2010 | 110 | 0.090 |
Why?
|
| Tissue Preservation | 1 | 2011 | 174 | 0.090 |
Why?
|
| Drug Synergism | 5 | 2017 | 1755 | 0.090 |
Why?
|
| Galectin 1 | 1 | 2011 | 128 | 0.090 |
Why?
|
| Transplantation Tolerance | 1 | 2015 | 605 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 379 | 0.090 |
Why?
|
| Utilization Review | 1 | 2011 | 382 | 0.080 |
Why?
|
| Cell Survival | 5 | 2014 | 5791 | 0.080 |
Why?
|
| Infant | 13 | 2023 | 36192 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 2 | 2011 | 510 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 244 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 3415 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 4740 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2020 | 3395 | 0.080 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 223 | 0.080 |
Why?
|
| OX40 Ligand | 2 | 2020 | 55 | 0.080 |
Why?
|
| Tissue Engineering | 2 | 2011 | 1868 | 0.080 |
Why?
|
| Benzamides | 3 | 2004 | 1370 | 0.080 |
Why?
|
| Proteoglycans | 3 | 1989 | 803 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1961 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 1 | 2010 | 343 | 0.080 |
Why?
|
| Interphase | 5 | 1999 | 228 | 0.080 |
Why?
|
| Diaphragm | 1 | 2011 | 351 | 0.080 |
Why?
|
| Germany | 1 | 2011 | 875 | 0.080 |
Why?
|
| Rabbits | 10 | 1995 | 4772 | 0.080 |
Why?
|
| Rectal Fistula | 1 | 2009 | 75 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 258 | 0.080 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 13380 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2011 | 1642 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 4876 | 0.080 |
Why?
|
| Alternative Splicing | 3 | 2006 | 1093 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2009 | 1349 | 0.080 |
Why?
|
| Bronchi | 1 | 2012 | 845 | 0.080 |
Why?
|
| Risk | 5 | 2011 | 9610 | 0.080 |
Why?
|
| Blotting, Northern | 4 | 2002 | 1545 | 0.080 |
Why?
|
| Receptor, Insulin | 1 | 2012 | 835 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 2872 | 0.080 |
Why?
|
| Calcium | 6 | 1999 | 5722 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2013 | 10766 | 0.080 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 4320 | 0.080 |
Why?
|
| Mycoses | 1 | 1991 | 386 | 0.080 |
Why?
|
| Cytotoxicity Tests, Immunologic | 5 | 1989 | 321 | 0.070 |
Why?
|
| Fecal Incontinence | 1 | 2010 | 241 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 1990 | 870 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 6 | 2006 | 352 | 0.070 |
Why?
|
| Phosphotyrosine | 3 | 1997 | 456 | 0.070 |
Why?
|
| Interleukin-17 | 3 | 2020 | 912 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3810 | 0.070 |
Why?
|
| Genotype | 6 | 2024 | 12990 | 0.070 |
Why?
|
| Emergency Treatment | 1 | 2011 | 496 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 589 | 0.070 |
Why?
|
| Risk Factors | 13 | 2018 | 74206 | 0.070 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 3 | 2001 | 93 | 0.070 |
Why?
|
| Drug Therapy, Combination | 4 | 2013 | 6310 | 0.070 |
Why?
|
| Homeodomain Proteins | 3 | 2007 | 2416 | 0.070 |
Why?
|
| Skin | 2 | 2020 | 4484 | 0.070 |
Why?
|
| Binding, Competitive | 4 | 1996 | 1141 | 0.070 |
Why?
|
| Disease Progression | 9 | 2022 | 13506 | 0.070 |
Why?
|
| Medical Order Entry Systems | 1 | 2012 | 521 | 0.070 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2008 | 208 | 0.070 |
Why?
|
| Immune System | 2 | 2002 | 796 | 0.070 |
Why?
|
| Thrombocytopenia | 2 | 2008 | 1181 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2007 | 140 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 803 | 0.070 |
Why?
|
| Tendons | 1 | 2011 | 558 | 0.070 |
Why?
|
| Antigens, Heterophile | 1 | 2006 | 70 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2865 | 0.070 |
Why?
|
| Hepatitis C | 1 | 1996 | 1584 | 0.070 |
Why?
|
| Bioprosthesis | 1 | 2011 | 591 | 0.070 |
Why?
|
| Mice, SCID | 3 | 2020 | 2626 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2017 | 3023 | 0.070 |
Why?
|
| Immunity, Cellular | 5 | 2002 | 1560 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 946 | 0.070 |
Why?
|
| Milk Proteins | 2 | 1998 | 163 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1159 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2020 | 2877 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 1192 | 0.060 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 5 | 1988 | 377 | 0.060 |
Why?
|
| Models, Animal | 2 | 2016 | 2112 | 0.060 |
Why?
|
| Translocation, Genetic | 2 | 2005 | 1393 | 0.060 |
Why?
|
| Immunohistochemistry | 5 | 2009 | 11076 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 883 | 0.060 |
Why?
|
| beta-Thalassemia | 1 | 2008 | 236 | 0.060 |
Why?
|
| Cloning, Molecular | 5 | 2006 | 4174 | 0.060 |
Why?
|
| Transcription, Genetic | 8 | 2018 | 7594 | 0.060 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2005 | 69 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 5796 | 0.060 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2011 | 499 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2021 | 2825 | 0.060 |
Why?
|
| Carcinoma | 1 | 2017 | 2330 | 0.060 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 1985 | 141 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2010 | 756 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2009 | 637 | 0.060 |
Why?
|
| Prosthesis Failure | 1 | 2010 | 1204 | 0.060 |
Why?
|
| Antigens, CD7 | 1 | 2024 | 30 | 0.060 |
Why?
|
| Lipid Bilayers | 1 | 1987 | 383 | 0.060 |
Why?
|
| RNA-Binding Proteins | 2 | 2005 | 1897 | 0.060 |
Why?
|
| Transfection | 5 | 1996 | 5774 | 0.060 |
Why?
|
| Age Factors | 7 | 2024 | 18395 | 0.060 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 1998 | 94 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 1749 | 0.060 |
Why?
|
| Ionomycin | 2 | 1996 | 110 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 2917 | 0.060 |
Why?
|
| Living Donors | 1 | 2009 | 641 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 4 | 1999 | 940 | 0.060 |
Why?
|
| Protein Array Analysis | 3 | 2012 | 400 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2529 | 0.060 |
Why?
|
| Reference Values | 2 | 2003 | 4920 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 315 | 0.060 |
Why?
|
| Multivariate Analysis | 6 | 2016 | 12059 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2005 | 375 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 5671 | 0.060 |
Why?
|
| Sezary Syndrome | 2 | 2002 | 80 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 1880 | 0.060 |
Why?
|
| Antigen-Antibody Reactions | 5 | 2011 | 340 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2005 | 410 | 0.060 |
Why?
|
| Patient Selection | 2 | 2020 | 4244 | 0.060 |
Why?
|
| Graft Rejection | 4 | 2011 | 4445 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 1827 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2014 | 2009 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 2822 | 0.060 |
Why?
|
| Lymphocytes, Null | 2 | 1982 | 13 | 0.060 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 291 | 0.060 |
Why?
|
| CHO Cells | 2 | 1996 | 1387 | 0.060 |
Why?
|
| Fatigue | 2 | 2008 | 1552 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 2155 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2013 | 23995 | 0.060 |
Why?
|
| Neprilysin | 8 | 1988 | 478 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2018 | 3482 | 0.060 |
Why?
|
| Health | 1 | 2006 | 398 | 0.050 |
Why?
|
| Italy | 1 | 2005 | 842 | 0.050 |
Why?
|
| Molecular Weight | 6 | 1993 | 2186 | 0.050 |
Why?
|
| Methods | 2 | 2002 | 1067 | 0.050 |
Why?
|
| ABO Blood-Group System | 2 | 1997 | 380 | 0.050 |
Why?
|
| Macrophages | 3 | 2017 | 5769 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2004 | 253 | 0.050 |
Why?
|
| Melphalan | 4 | 2019 | 420 | 0.050 |
Why?
|
| Thrombomodulin | 2 | 2016 | 105 | 0.050 |
Why?
|
| Intestines | 1 | 2012 | 1909 | 0.050 |
Why?
|
| Culture Media, Conditioned | 2 | 1996 | 522 | 0.050 |
Why?
|
| Secondary Prevention | 3 | 2010 | 1475 | 0.050 |
Why?
|
| Blood Group Incompatibility | 2 | 2008 | 135 | 0.050 |
Why?
|
| Kinetics | 6 | 2015 | 6374 | 0.050 |
Why?
|
| Cricetinae | 2 | 1996 | 2423 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 6 | 2017 | 1435 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2024 | 12341 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5315 | 0.050 |
Why?
|
| Receptors, Fc | 4 | 1992 | 535 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2024 | 469 | 0.050 |
Why?
|
| Appendicitis | 1 | 2009 | 675 | 0.050 |
Why?
|
| RNA, Neoplasm | 4 | 2007 | 750 | 0.050 |
Why?
|
| Globins | 1 | 2003 | 404 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2021 | 793 | 0.050 |
Why?
|
| Plant Proteins | 3 | 1994 | 370 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2013 | 2479 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2013 | 2885 | 0.050 |
Why?
|
| Kidney | 1 | 2018 | 7048 | 0.050 |
Why?
|
| Bone Marrow Examination | 1 | 2002 | 154 | 0.050 |
Why?
|
| Alleles | 3 | 2021 | 6863 | 0.050 |
Why?
|
| DNA Nucleotidylexotransferase | 2 | 1996 | 64 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4431 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2022 | 8631 | 0.050 |
Why?
|
| Ferritins | 2 | 2020 | 598 | 0.050 |
Why?
|
| Consensus | 2 | 2023 | 3123 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 4 | 2016 | 647 | 0.050 |
Why?
|
| C-Peptide | 1 | 2024 | 440 | 0.050 |
Why?
|
| Th1 Cells | 2 | 1998 | 1036 | 0.050 |
Why?
|
| Polymorphism, Genetic | 3 | 2009 | 4243 | 0.050 |
Why?
|
| Microarray Analysis | 1 | 2005 | 749 | 0.050 |
Why?
|
| Cohort Studies | 10 | 2018 | 41487 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 1999 | 364 | 0.050 |
Why?
|
| Th2 Cells | 2 | 1998 | 1060 | 0.050 |
Why?
|
| Comorbidity | 3 | 2014 | 10508 | 0.050 |
Why?
|
| Decontamination | 1 | 2022 | 73 | 0.050 |
Why?
|
| Interferon-alpha | 5 | 2011 | 921 | 0.050 |
Why?
|
| Cell Membrane | 6 | 2005 | 3688 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2010 | 2116 | 0.050 |
Why?
|
| Pulmonary Fibrosis | 3 | 2017 | 505 | 0.050 |
Why?
|
| Bacterial Infections | 3 | 1996 | 1390 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 5789 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 15842 | 0.050 |
Why?
|
| Testis | 2 | 2004 | 794 | 0.050 |
Why?
|
| Transcription Factors | 3 | 2014 | 12128 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2014 | 4352 | 0.050 |
Why?
|
| Erythrocytes | 5 | 2016 | 2413 | 0.050 |
Why?
|
| Cytarabine | 2 | 2008 | 697 | 0.050 |
Why?
|
| Critical Illness | 1 | 1994 | 2723 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 326 | 0.050 |
Why?
|
| Antigens, CD20 | 2 | 2014 | 200 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 290 | 0.050 |
Why?
|
| Cell Death | 2 | 2018 | 1678 | 0.050 |
Why?
|
| Macromolecular Substances | 6 | 1990 | 1434 | 0.050 |
Why?
|
| Ciprofloxacin | 2 | 1995 | 312 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2021 | 91 | 0.050 |
Why?
|
| Methylation | 2 | 2021 | 1084 | 0.050 |
Why?
|
| Models, Biological | 2 | 2015 | 9469 | 0.050 |
Why?
|
| HIV-1 | 1 | 2018 | 6863 | 0.050 |
Why?
|
| Interleukin-1 | 2 | 1996 | 1248 | 0.040 |
Why?
|
| Blotting, Southern | 4 | 1998 | 777 | 0.040 |
Why?
|
| Cross-Linking Reagents | 2 | 1994 | 687 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 4915 | 0.040 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2002 | 195 | 0.040 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2000 | 87 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 3734 | 0.040 |
Why?
|
| Salvage Therapy | 3 | 2019 | 1264 | 0.040 |
Why?
|
| Vital Capacity | 2 | 2014 | 971 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2024 | 549 | 0.040 |
Why?
|
| Intracellular Fluid | 2 | 1998 | 201 | 0.040 |
Why?
|
| Immunoglobulins | 2 | 2016 | 853 | 0.040 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2000 | 121 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1995 | 817 | 0.040 |
Why?
|
| Contrast Media | 1 | 2013 | 5311 | 0.040 |
Why?
|
| Phosphoproteins | 4 | 2001 | 2448 | 0.040 |
Why?
|
| DNA Methylation | 3 | 2022 | 4398 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 1334 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2008 | 3606 | 0.040 |
Why?
|
| HLA-DR7 Antigen | 2 | 1996 | 27 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1992 | 767 | 0.040 |
Why?
|
| Inflammation | 2 | 2016 | 10773 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2007 | 2510 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 2001 | 232 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2001 | 452 | 0.040 |
Why?
|
| Terminology as Topic | 3 | 2016 | 1530 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 9539 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 1999 | 1379 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 1999 | 56 | 0.040 |
Why?
|
| Multienzyme Complexes | 2 | 2001 | 666 | 0.040 |
Why?
|
| Putamen | 1 | 2020 | 292 | 0.040 |
Why?
|
| Lymphocytosis | 1 | 2000 | 121 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2001 | 4615 | 0.040 |
Why?
|
| Glycoproteins | 5 | 1986 | 2203 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 1999 | 617 | 0.040 |
Why?
|
| Temperature | 3 | 2011 | 2226 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 3164 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2000 | 419 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2002 | 560 | 0.040 |
Why?
|
| Cell Cycle | 5 | 1998 | 2932 | 0.040 |
Why?
|
| Receptors, Very Late Antigen | 2 | 1997 | 74 | 0.040 |
Why?
|
| Laser Coagulation | 1 | 2001 | 330 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2018 | 2803 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 2001 | 551 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2005 | 2707 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2007 | 1302 | 0.040 |
Why?
|
| Membrane Proteins | 7 | 2005 | 7856 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 3712 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2019 | 87 | 0.040 |
Why?
|
| 4-1BB Ligand | 1 | 2018 | 29 | 0.040 |
Why?
|
| Receptors, Mitogen | 1 | 1998 | 61 | 0.040 |
Why?
|
| Forced Expiratory Volume | 2 | 2014 | 1814 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2003 | 1813 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 2016 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2009 | 5492 | 0.040 |
Why?
|
| Genetic Markers | 3 | 2017 | 2601 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2018 | 210 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 1626 | 0.040 |
Why?
|
| Epigenomics | 1 | 2023 | 943 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 2 | 1996 | 285 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 2 | 2012 | 248 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2010 | 2017 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1997 | 141 | 0.040 |
Why?
|
| HIV Infections | 3 | 2018 | 17351 | 0.040 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 102 | 0.040 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 4111 | 0.040 |
Why?
|
| Hemagglutinins | 1 | 1997 | 113 | 0.040 |
Why?
|
| Muscles | 1 | 2002 | 1576 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 1997 | 203 | 0.040 |
Why?
|
| Feedback | 1 | 2001 | 791 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 1998 | 185 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 4249 | 0.040 |
Why?
|
| Basal Ganglia | 1 | 2020 | 554 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2005 | 6343 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1999 | 412 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 346 | 0.030 |
Why?
|
| Blood Component Transfusion | 1 | 1997 | 142 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1998 | 262 | 0.030 |
Why?
|
| Galactosylceramides | 1 | 2017 | 92 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 1997 | 115 | 0.030 |
Why?
|
| Penis | 1 | 1998 | 212 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2017 | 123 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 1738 | 0.030 |
Why?
|
| Spleen | 3 | 2016 | 2295 | 0.030 |
Why?
|
| United States | 6 | 2021 | 72334 | 0.030 |
Why?
|
| Urticaria Pigmentosa | 1 | 1976 | 16 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 1987 | 4936 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 1126 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1996 | 228 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1999 | 778 | 0.030 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 301 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2016 | 153 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 20098 | 0.030 |
Why?
|
| N-Glycosyl Hydrolases | 2 | 1986 | 68 | 0.030 |
Why?
|
| Angiopoietin-1 | 1 | 2016 | 122 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2000 | 417 | 0.030 |
Why?
|
| Ionophores | 1 | 1996 | 107 | 0.030 |
Why?
|
| Workflow | 1 | 2021 | 851 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 221 | 0.030 |
Why?
|
| Gangliosides | 1 | 1996 | 132 | 0.030 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2016 | 100 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 1996 | 2219 | 0.030 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 172 | 0.030 |
Why?
|
| Nuclear Family | 1 | 1996 | 311 | 0.030 |
Why?
|
| Binding Sites, Antibody | 2 | 1994 | 337 | 0.030 |
Why?
|
| Rheumatoid Factor | 1 | 1976 | 185 | 0.030 |
Why?
|
| Lung Diseases | 2 | 2019 | 1909 | 0.030 |
Why?
|
| Cell Count | 2 | 2016 | 1835 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2002 | 1233 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1996 | 430 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 2691 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14605 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2018 | 469 | 0.030 |
Why?
|
| Serine | 1 | 1999 | 830 | 0.030 |
Why?
|
| Brain | 2 | 2018 | 27112 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 152 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1995 | 91 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2011 | 3816 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2016 | 225 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 86 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2001 | 1320 | 0.030 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2014 | 32 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 3 | 1999 | 30 | 0.030 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 58976 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2811 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 352 | 0.030 |
Why?
|
| Antigen Presentation | 2 | 2010 | 1251 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 605 | 0.030 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1994 | 221 | 0.030 |
Why?
|
| Plasma | 1 | 1997 | 586 | 0.030 |
Why?
|
| Sphingosine | 1 | 2016 | 308 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 1809 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1999 | 1246 | 0.030 |
Why?
|
| Clonal Anergy | 1 | 1994 | 170 | 0.030 |
Why?
|
| Immunoblotting | 3 | 2012 | 1646 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 1996 | 2561 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 452 | 0.030 |
Why?
|
| Forecasting | 1 | 2003 | 2928 | 0.030 |
Why?
|
| Receptors, Formyl Peptide | 1 | 1994 | 146 | 0.030 |
Why?
|
| Lysophospholipids | 1 | 2016 | 338 | 0.030 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2016 | 172 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 1994 | 100 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 1994 | 91 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 712 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 7879 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2019 | 2202 | 0.030 |
Why?
|
| Nervous System | 1 | 1997 | 545 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 1989 | 545 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 2019 | 3156 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 678 | 0.030 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 4853 | 0.030 |
Why?
|
| Computational Biology | 1 | 2005 | 3518 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2003 | 2639 | 0.030 |
Why?
|
| Bronchography | 1 | 2012 | 75 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2000 | 1092 | 0.030 |
Why?
|
| Receptors, Peptide | 1 | 1994 | 279 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 350 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2017 | 719 | 0.030 |
Why?
|
| Neural Conduction | 1 | 1994 | 441 | 0.030 |
Why?
|
| Vincristine | 4 | 1998 | 1036 | 0.030 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1992 | 40 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2014 | 522 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 1971 | 0.030 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2011 | 25 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1994 | 477 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 5840 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1992 | 91 | 0.020 |
Why?
|
| Death | 1 | 2016 | 676 | 0.020 |
Why?
|
| Sheep | 3 | 2011 | 1440 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2013 | 532 | 0.020 |
Why?
|
| Morpholines | 1 | 2015 | 581 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 1994 | 903 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Sex Factors | 2 | 2019 | 10552 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2012 | 133 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 903 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2395 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 3429 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 1991 | 128 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2017 | 1175 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2020 | 4278 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2011 | 84 | 0.020 |
Why?
|
| Host vs Graft Reaction | 1 | 1990 | 13 | 0.020 |
Why?
|
| Cell Nucleus | 2 | 2016 | 2909 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2018 | 1948 | 0.020 |
Why?
|
| Chimera | 2 | 1990 | 453 | 0.020 |
Why?
|
| Amphotericin B | 1 | 1991 | 142 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 1974 | 0.020 |
Why?
|
| RNA | 3 | 1998 | 2726 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2015 | 573 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 527 | 0.020 |
Why?
|
| Transgenes | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Biological Products | 1 | 2020 | 914 | 0.020 |
Why?
|
| Aftercare | 1 | 2017 | 914 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 371 | 0.020 |
Why?
|
| Caspases | 1 | 2014 | 879 | 0.020 |
Why?
|
| Aging | 1 | 2010 | 8708 | 0.020 |
Why?
|
| Hybrid Cells | 2 | 1981 | 422 | 0.020 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2012 | 197 | 0.020 |
Why?
|
| DNA Primers | 3 | 2003 | 2819 | 0.020 |
Why?
|
| Immunoglobulin A | 2 | 2009 | 978 | 0.020 |
Why?
|
| Cell Size | 1 | 2012 | 624 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2016 | 1206 | 0.020 |
Why?
|
| Eye Infections, Fungal | 1 | 1991 | 100 | 0.020 |
Why?
|
| Splenectomy | 1 | 1992 | 391 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 339 | 0.020 |
Why?
|
| Granulocytes | 2 | 1983 | 551 | 0.020 |
Why?
|
| Protein Isoforms | 2 | 2006 | 1699 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 26125 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2571 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 1991 | 523 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 71 | 0.020 |
Why?
|
| Observation | 1 | 2011 | 310 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1990 | 102 | 0.020 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2011 | 245 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 246 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 316 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1991 | 779 | 0.020 |
Why?
|
| Insulin | 1 | 2024 | 6596 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 867 | 0.020 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1991 | 251 | 0.020 |
Why?
|
| Multipotent Stem Cells | 1 | 2011 | 200 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 321 | 0.020 |
Why?
|
| Fibrosis | 1 | 2016 | 2049 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 132 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 14031 | 0.020 |
Why?
|
| Complement Activation | 1 | 1991 | 445 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2010 | 239 | 0.020 |
Why?
|
| Adenine | 1 | 2014 | 987 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 221 | 0.020 |
Why?
|
| Carboxypeptidases | 1 | 1989 | 154 | 0.020 |
Why?
|
| Electromyography | 1 | 1994 | 1394 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3826 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 297 | 0.020 |
Why?
|
| Sulfur Radioisotopes | 1 | 1988 | 113 | 0.020 |
Why?
|
| Nucleic Acids | 1 | 2011 | 188 | 0.020 |
Why?
|
| Amniocentesis | 1 | 2008 | 115 | 0.020 |
Why?
|
| Proportional Hazards Models | 4 | 2005 | 12463 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2010 | 250 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 1509 | 0.020 |
Why?
|
| DNA | 5 | 1999 | 7212 | 0.020 |
Why?
|
| Fetus | 2 | 1987 | 1863 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2008 | 76 | 0.020 |
Why?
|
| Syndrome | 1 | 2014 | 3267 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1893 | 0.020 |
Why?
|
| Ribosomes | 2 | 1994 | 501 | 0.020 |
Why?
|
| E-Selectin | 1 | 2010 | 576 | 0.020 |
Why?
|
| Liver | 3 | 2016 | 7529 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1992 | 664 | 0.020 |
Why?
|
| Pyridines | 2 | 2015 | 2875 | 0.020 |
Why?
|
| Education | 1 | 2010 | 537 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 2243 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 1994 | 2206 | 0.020 |
Why?
|
| Doxorubicin | 3 | 1998 | 2224 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1987 | 592 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 10209 | 0.020 |
Why?
|
| Protein Binding | 2 | 2014 | 9351 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 934 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 673 | 0.020 |
Why?
|
| Medication Errors | 1 | 2012 | 783 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1862 | 0.020 |
Why?
|
| Chondroitin | 1 | 1985 | 64 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1656 | 0.020 |
Why?
|
| Genes, ras | 1 | 1988 | 654 | 0.020 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2005 | 62 | 0.020 |
Why?
|
| Myeloma Proteins | 2 | 1989 | 71 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 1985 | 174 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 3492 | 0.020 |
Why?
|
| Mitogens | 2 | 1985 | 230 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2010 | 606 | 0.020 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 3 | 1994 | 27 | 0.020 |
Why?
|
| Enzyme Precursors | 1 | 2005 | 170 | 0.020 |
Why?
|
| Overweight | 1 | 2016 | 2417 | 0.020 |
Why?
|
| Wound Healing | 1 | 2016 | 2805 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2011 | 1330 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2010 | 754 | 0.020 |
Why?
|
| Binding Sites | 1 | 1993 | 6055 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2010 | 823 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1996 | 3032 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1985 | 373 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 17904 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1986 | 357 | 0.010 |
Why?
|
| Staurosporine | 1 | 2005 | 242 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1985 | 814 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 1983 | 138 | 0.010 |
Why?
|
| Cell Adhesion | 2 | 1994 | 3087 | 0.010 |
Why?
|
| Hybridomas | 1 | 1985 | 442 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1983 | 175 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 6485 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3092 | 0.010 |
Why?
|
| Heart | 1 | 1997 | 4404 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1989 | 1022 | 0.010 |
Why?
|
| Mathematics | 1 | 1985 | 707 | 0.010 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 1263 | 0.010 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 1 | 1983 | 45 | 0.010 |
Why?
|
| California | 1 | 1987 | 1429 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2008 | 702 | 0.010 |
Why?
|
| Interferon Type I | 2 | 1989 | 562 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 1983 | 192 | 0.010 |
Why?
|
| Phospholipids | 1 | 1987 | 786 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 718 | 0.010 |
Why?
|
| Disulfides | 3 | 1994 | 465 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2008 | 1173 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1985 | 1741 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2001 | 36426 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1994 | 1922 | 0.010 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2002 | 50 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 1664 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 3 | 1990 | 1624 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 2 | 1997 | 361 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1998 | 4026 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2011 | 2161 | 0.010 |
Why?
|
| Genes | 1 | 1986 | 1823 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2006 | 718 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 1702 | 0.010 |
Why?
|
| Biometry | 1 | 2005 | 563 | 0.010 |
Why?
|
| Methylcellulose | 1 | 1981 | 34 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2007 | 727 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2002 | 247 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 1386 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2005 | 495 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2002 | 287 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8654 | 0.010 |
Why?
|
| Lymph Nodes | 3 | 1989 | 3466 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 372 | 0.010 |
Why?
|
| Phorbols | 1 | 1981 | 43 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 1935 | 0.010 |
Why?
|
| Population | 1 | 1981 | 141 | 0.010 |
Why?
|
| Neoplasms, Experimental | 2 | 2002 | 1229 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2001 | 68 | 0.010 |
Why?
|
| beta Catenin | 1 | 2006 | 1040 | 0.010 |
Why?
|
| Fever | 1 | 2008 | 1618 | 0.010 |
Why?
|
| Antigens | 2 | 1986 | 1443 | 0.010 |
Why?
|
| Genes, fos | 1 | 2001 | 176 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1987 | 1787 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1985 | 1519 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2005 | 1202 | 0.010 |
Why?
|
| Diagnosis, Differential | 3 | 1992 | 12974 | 0.010 |
Why?
|
| Thymus Neoplasms | 1 | 1983 | 274 | 0.010 |
Why?
|
| Immune Sera | 4 | 1981 | 606 | 0.010 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 598 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 882 | 0.010 |
Why?
|
| Culture Media | 2 | 1998 | 897 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2001 | 740 | 0.010 |
Why?
|
| Gestational Age | 1 | 2008 | 3577 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1985 | 1756 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 1979 | 434 | 0.010 |
Why?
|
| Receptors, Interleukin-15 | 1 | 1998 | 13 | 0.010 |
Why?
|
| Dogs | 1 | 1983 | 3839 | 0.010 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 1 | 1998 | 195 | 0.010 |
Why?
|
| Immunoglobulin M | 3 | 1995 | 1527 | 0.010 |
Why?
|
| Anesthesia, Local | 1 | 2001 | 277 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 2244 | 0.010 |
Why?
|
| Databases, Factual | 1 | 1994 | 7967 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1999 | 363 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11121 | 0.010 |
Why?
|
| Receptors, IgE | 2 | 1990 | 375 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 1999 | 169 | 0.010 |
Why?
|
| Citrates | 1 | 1998 | 134 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1998 | 176 | 0.010 |
Why?
|
| Microspheres | 1 | 2001 | 784 | 0.010 |
Why?
|
| Pregnancy | 2 | 2011 | 29874 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 1997 | 119 | 0.010 |
Why?
|
| Adsorption | 1 | 1997 | 197 | 0.010 |
Why?
|
| Lung | 1 | 2016 | 10000 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 441 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1997 | 239 | 0.010 |
Why?
|
| GATA1 Transcription Factor | 1 | 1998 | 296 | 0.010 |
Why?
|
| Eosinophils | 1 | 2002 | 950 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 237 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2010 | 3548 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2005 | 2330 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1997 | 216 | 0.010 |
Why?
|
| Prevalence | 1 | 2014 | 15732 | 0.010 |
Why?
|
| Receptors, Interleukin-9 | 1 | 1996 | 4 | 0.010 |
Why?
|
| Genome, Human | 1 | 2009 | 4425 | 0.010 |
Why?
|
| Receptors, Interleukin-7 | 1 | 1996 | 40 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1998 | 387 | 0.010 |
Why?
|
| Receptors, Interleukin-4 | 1 | 1996 | 64 | 0.010 |
Why?
|
| Osteosclerosis | 1 | 1976 | 42 | 0.010 |
Why?
|
| HIV Protease Inhibitors | 1 | 1998 | 432 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 1150 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 321 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1999 | 687 | 0.010 |
Why?
|
| Freezing | 1 | 1996 | 311 | 0.010 |
Why?
|
| DNA Probes | 1 | 1996 | 541 | 0.010 |
Why?
|
| Macaca mulatta | 3 | 1986 | 2329 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1981 | 1154 | 0.010 |
Why?
|
| STAT6 Transcription Factor | 1 | 1995 | 194 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1998 | 621 | 0.010 |
Why?
|
| Dimerization | 1 | 1996 | 891 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 1085 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2009 | 26198 | 0.010 |
Why?
|
| Massachusetts | 1 | 1987 | 8830 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 2 | 1985 | 550 | 0.010 |
Why?
|
| Fever of Unknown Origin | 1 | 1995 | 94 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1983 | 2242 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1999 | 1494 | 0.010 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 1996 | 359 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1989 | 445 | 0.010 |
Why?
|
| Methionine | 3 | 1981 | 572 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1976 | 393 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 3442 | 0.010 |
Why?
|
| Lymphoma, T-Cell | 1 | 1996 | 304 | 0.010 |
Why?
|
| Rats | 2 | 1994 | 23742 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 1988 | 3220 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 1999 | 1115 | 0.010 |
Why?
|
| Imidazoles | 1 | 1999 | 1180 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 42 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1998 | 947 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 1998 | 1136 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1994 | 1157 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1995 | 825 | 0.010 |
Why?
|
| Thiolester Hydrolases | 1 | 1992 | 90 | 0.010 |
Why?
|
| Creatinine | 1 | 1997 | 1899 | 0.010 |
Why?
|
| Paraproteins | 1 | 1991 | 38 | 0.010 |
Why?
|
| Chemical Precipitation | 2 | 1981 | 175 | 0.010 |
Why?
|
| Software | 1 | 2005 | 4434 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2000 | 1157 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1992 | 641 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1992 | 347 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 5079 | 0.010 |
Why?
|
| Heparin | 1 | 1998 | 1634 | 0.010 |
Why?
|
| Drug Costs | 1 | 1998 | 1183 | 0.010 |
Why?
|
| Biological Availability | 1 | 1991 | 390 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 1999 | 2455 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1990 | 262 | 0.010 |
Why?
|
| Transforming Growth Factors | 1 | 1988 | 75 | 0.000 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 1989 | 157 | 0.000 |
Why?
|
| Serum Albumin | 1 | 1992 | 672 | 0.000 |
Why?
|
| Cell Fractionation | 1 | 1989 | 251 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1992 | 1463 | 0.000 |
Why?
|
| Hyperglycemia | 1 | 1997 | 1376 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1989 | 645 | 0.000 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1988 | 158 | 0.000 |
Why?
|
| Quality of Life | 1 | 2009 | 13367 | 0.000 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 1386 | 0.000 |
Why?
|
| Knee Joint | 1 | 1976 | 1676 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15266 | 0.000 |
Why?
|
| Granzymes | 1 | 1989 | 277 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1995 | 4021 | 0.000 |
Why?
|
| Ammonium Chloride | 1 | 1986 | 72 | 0.000 |
Why?
|
| Skin Tests | 1 | 1988 | 637 | 0.000 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1987 | 285 | 0.000 |
Why?
|
| Probability | 1 | 1991 | 2477 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1985 | 299 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1988 | 497 | 0.000 |
Why?
|
| Boston | 1 | 1998 | 9326 | 0.000 |
Why?
|
| Antigens, Viral | 1 | 1989 | 988 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1986 | 698 | 0.000 |
Why?
|
| Germ-Free Life | 1 | 1985 | 189 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1990 | 710 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1985 | 531 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1992 | 21012 | 0.000 |
Why?
|
| Cause of Death | 1 | 1995 | 3683 | 0.000 |
Why?
|
| Lymphokines | 1 | 1987 | 927 | 0.000 |
Why?
|
| Immunoglobulin E | 1 | 1990 | 1502 | 0.000 |
Why?
|
| Liver Diseases | 1 | 1992 | 1298 | 0.000 |
Why?
|
| Phorbol Esters | 1 | 1982 | 108 | 0.000 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1986 | 621 | 0.000 |
Why?
|
| Viral Proteins | 1 | 1989 | 1804 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1998 | 4812 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1988 | 1768 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1989 | 3968 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1981 | 509 | 0.000 |
Why?
|
| Plant Lectins | 1 | 1981 | 103 | 0.000 |
Why?
|
| Galactose Oxidase | 1 | 1980 | 12 | 0.000 |
Why?
|
| Borohydrides | 1 | 1980 | 32 | 0.000 |
Why?
|
| Fabaceae | 1 | 1981 | 103 | 0.000 |
Why?
|
| Plants, Medicinal | 1 | 1981 | 165 | 0.000 |
Why?
|
| Cell Membrane Permeability | 1 | 1982 | 575 | 0.000 |
Why?
|
| Absorption | 1 | 1979 | 242 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1980 | 384 | 0.000 |
Why?
|
| Lectins | 1 | 1981 | 491 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1980 | 464 | 0.000 |
Why?
|
| Megakaryocytes | 1 | 1983 | 566 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1983 | 1510 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1981 | 1031 | 0.000 |
Why?
|
| DNA Replication | 1 | 1982 | 1418 | 0.000 |
Why?
|
| Regeneration | 1 | 1983 | 1511 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1985 | 3312 | 0.000 |
Why?
|